Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | APAF1 | O14727 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27749752 | 0.87 | KDM4E (0.57) | IDO1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL2687045 | 0.85 | KDM4E (0.64) | IDO1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL8685889 | 0.84 | IDO1 (0.55) | IDO1KDM4EALDH1A1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL3150864 | 0.83 | IDO1 (0.54) | IDO1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL13203774 | 0.81 | NR4A2 (0.55) | IDO1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL2184960 | 0.81 | NR4A2 (0.55) | IDO1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL28370254 | 0.80 | NR4A2 (0.37) | IDO1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL29003631 | 0.80 | KDM4E (0.62) | IDO1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL4543449 | 0.80 | MTNR1B (0.41) | IDO1KDM4ELMNAGAA | |
| SCHEMBL2395366 | 0.79 | ALOX5 (0.53) | IDO1KDM4EALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117969859-B | Metabolic biomarker for polycystic ovary syndrome and application thereof | 山东大学 | 2024-09-06 | — | — | CN | claimed |
| CN-117969859-A | Metabolic biomarker for polycystic ovary syndrome and application thereof | 山东大学 | 2024-05-03 | — | — | CN | claimed |
| CN-117969859-B | Metabolic biomarker for polycystic ovary syndrome and application thereof | 山东大学 | 2024-09-06 | — | — | CN | disclosed |
| CN-117969859-A | Metabolic biomarker for polycystic ovary syndrome and application thereof | 山东大学 | 2024-05-03 | — | — | CN | disclosed |
| US-9206156-B2 | Substituted indole derivatives | Grünenthal GmbH (DE) | 2015-12-08 | — | — | US | disclosed |
| US-20130116283-A1 | Substituted indole derivatives | Grünenthal GmbH (DE) | 2013-05-09 | — | — | US | disclosed |
| US-20090215828-A1 | Substituted indole derivatives | GRUNENTHAL GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215828-A1 | Substituted indole derivatives | IDO1, IDO2, TPH1 | IDO1 1/4885KDM4E 2535/4885ALDH1A1 886/4885 |
| US-20130116283-A1 | Substituted indole derivatives | IDO1, IDO2, TPH1 | IDO1 1/4885KDM4E 2535/4885ALDH1A1 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.